Table I.

Pharmacodynamic Parameter Estimates of Crizotinib-Mediated ALK or MET Inhibition in Mouse Xenograft Models with H3122 NSCLC or GTL16 GC Cells Following Once Daily Oral Administration

Study	Model	EC 50	E 0	E max	k e0	γ
		ng/mL			h −1
ALK-1	I	233 (153)	1 (fixed)	1 (fixed)	0.030 (0.013)	0.56 (0.11)
MET-1	I	18.5 (2.65)	1 (fixed)	1 (fixed)	0.135 (0.020)	1 (fixed)

Precision of the estimates is expressed as S.E. in parentheses

Study ALK-1: athymic nu/nu mice bearing H3122 NSCLC xenografts; Study MET-1: athymic nu/nu mice bearing GTL16 GC xenografts

Results are cited from previous reports (21,22)